HanAll Biopharma Co Ltd (009420):企業の財務・戦略的SWOT分析

◆英語タイトル:HanAll Biopharma Co Ltd (009420) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH81901FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
HanAll Biopharma Co Ltd (HanAll), formerly HanAll Pharmaceutical Co Ltd, is a developer of generic and specialty drugs for treatment of diseases related to digestive, endocrine, musculoskeletal and urinary system. The company’s pipeline products include HL036, a drug being developed for treating dry eye diseases; HL189 against non-infectious uveitis; IM156 targeting cancers; and HL190 to treat wet age-related macular degeneration. It also sells drugs for treating digestive dysfunction, osteoporosis, liver dysfunction, hepatic coma, metabolic disorders caused due to hypocalcemia, tetania, bone pain and bone lesions. HanAll also conducts research for developing drugs in the therapeutic areas of autoimmune, eye diseases and immuno oncology indications. The company works in partnership with global pharmaceutical companies and academic institutions for advancing its pipeline products. It has operations in South Korea and the US. HanAll is headquartered in Seoul, South Korea

HanAll Biopharma Co Ltd Key Recent Developments

Jan 19,2021: Hanall Biopharma, net profit in 2020 increased by 14% from the previous year to KRW 21.9 billion
Oct 29,2020: Hanall Biopharma achieved sales of 22.1 billion won, operating profit of 1 billion, and net profit of 3.7 billion in the third quarter
Jul 29,2020: Hanol Biopharma achieved 22.6 billion won in sales in 2Q and 1.6 billion in operating profit

This comprehensive SWOT profile of HanAll Biopharma Co Ltd provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of HanAll Biopharma Co Ltd including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

HanAll Biopharma Co Ltd – Key Information
HanAll Biopharma Co Ltd – Overview
HanAll Biopharma Co Ltd – Key Employees
HanAll Biopharma Co Ltd – Key Employee Biographies
HanAll Biopharma Co Ltd – Key Operational Heads
HanAll Biopharma Co Ltd – Major Products and Services
HanAll Biopharma Co Ltd – History
HanAll Biopharma Co Ltd – Company Statement
HanAll Biopharma Co Ltd – Locations And Subsidiaries
HanAll Biopharma Co Ltd
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

HanAll Biopharma Co Ltd – Business Description
HanAll Biopharma Co Ltd – Corporate Strategy
HanAll Biopharma Co Ltd – SWOT Analysis
SWOT Analysis – Overview
HanAll Biopharma Co Ltd – Strengths
HanAll Biopharma Co Ltd – Weaknesses
HanAll Biopharma Co Ltd – Opportunities
HanAll Biopharma Co Ltd – Threats
HanAll Biopharma Co Ltd – Key Competitors

Section 3 – Company Financial Performance Charts

HanAll Biopharma Co Ltd – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

HanAll Biopharma Co Ltd, Key Information
HanAll Biopharma Co Ltd, Key Ratios
HanAll Biopharma Co Ltd, Share Data
HanAll Biopharma Co Ltd, Major Products and Services
HanAll Biopharma Co Ltd, History
HanAll Biopharma Co Ltd, Key Employees
HanAll Biopharma Co Ltd, Key Employee Biographies
HanAll Biopharma Co Ltd, Key Operational Heads
HanAll Biopharma Co Ltd, Other Locations
HanAll Biopharma Co Ltd, Subsidiaries
HanAll Biopharma Co Ltd, Key Competitors
HanAll Biopharma Co Ltd, SWOT Analysis
HanAll Biopharma Co Ltd, Ratios based on current share price
HanAll Biopharma Co Ltd, Annual Ratios
HanAll Biopharma Co Ltd, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[HanAll Biopharma Co Ltd (009420):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ADMA Biologics Inc (ADMA):企業の財務・戦略的SWOT分析
    ADMA Biologics Inc (ADMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Rashtriya Chemicals and Fertilizers Ltd (RCF):企業の財務・戦略的SWOT分析
    Summary Rashtriya Chemicals and Fertilizers Ltd (RCFL) is a chemical company that manufactures and markets fertilizers and industrial chemicals. The company offers industrial chemicals include methanol, mono methylamine, strong nitric acid, dilute nitric acid, sulphuric acid, sodium nitrite, anhydro …
  • Aromatech SAS:企業の戦略・SWOT・財務情報
    Aromatech SAS - Strategy, SWOT and Corporate Finance Report Summary Aromatech SAS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Pentair plc (PNR)-石油・ガス分野:企業M&A・提携分析
    Summary Pentair plc (Pentair) is an industrial manufacturing company. It designs, manufactures and markets water system products and solutions for filtration, separation and fluid process management; and products that guard sensitive electrical and electronic equipment; and heat management solutions …
  • UCB SA (UCB)-製薬・医療分野:企業M&A・提携分析
    Summary UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines …
  • Activision Blizzard, Inc.
    Activision Blizzard, Inc. - Strategy, SWOT and Corporate Finance Report Summary Activision Blizzard, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Carl Zeiss Meditec Inc.:医療機器:M&Aディール及び事業提携情報
    Summary Carl Zeiss Meditec Inc (Carl Zeiss Meditec), a subsidiary of Carl Zeiss Meditec AG is a medical technology company that manufactures and markets various healthcare products. The company provides ophthalmology and optometry products, neurosurgery products, ENT products, spine surgery products …
  • Teleflex Incorporated:戦略・SWOT・企業財務分析
    Teleflex Incorporated - Strategy, SWOT and Corporate Finance Report Summary Teleflex Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Vital Images Inc:企業の戦略的SWOT分析
    Vital Images Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Impresario Entertainment and Hospitality Pvt., Ltd.:企業の戦略・SWOT・財務情報
    Impresario Entertainment and Hospitality Pvt., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Impresario Entertainment and Hospitality Pvt., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's stru …
  • Adenovir Pharma AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Adenovir Pharma AB (Adenovir Pharma) focuses on the development of antiviral pharmaceutical solutions for the treatment of infectious eye diseases such as adenoviral conjunctivitis and epidemic keratoconjunctivitis (EKC). The company’s APD-209 is topical pharmaceutical product that prevents …
  • Vivus, Inc.:企業の戦略・SWOT・財務分析
    Vivus, Inc. - Strategy, SWOT and Corporate Finance Report Summary Vivus, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Universal Electronics Inc (UEIC):企業の財務・戦略的SWOT分析
    Summary Universal Electronics Inc (Universal Electronics) is a technology company that offers control and sensor technology solutions. The company offers a range of pre-programmed and universal remote control products, audio-video accessories, intelligent wireless security and automation components, …
  • Sumitomo Corp (8053):石油・ガス:M&Aディール及び事業提携情報
    Summary Sumitomo Corp (Sumitomo) is a multifaceted business enterprise. It operates various businesses such as metal products, transportation, construction systems, infrastructure, media, network & lifestyle retail, general products, real estate, financial services, logistics, mineral resources and …
  • PJSC MegaFon:企業のM&A・事業提携・投資動向
    PJSC MegaFon - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's PJSC MegaFon Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Refocus Group Inc:製品パイプライン分析
    Summary Refocus Group Inc (Refocus Group) is a medical equipment company that concentrates on research and development of treatments for human vision disorders. The company has developed visability implant system (VIS) for the treatment of presbyopia. Its VIS procedure is an outpatient procedure tha …
  • OncoSil Medical Ltd (OSL):企業の財務・戦略的SWOT分析
    Summary OncoSil Medical Ltd (OncoSil), is a medical device company that develops and commercializes products for the treatment of pancreatic and liver cancer. The company’s lead product includes oncosil, a brachytherapy device that emits beta radiation and is implanted directly inside the cancerous …
  • San Leon Energy Plc (SLE):石油・ガス:M&Aディール及び事業提携情報
    Summary San Leon Energy Plc (San Leon) is an oil and gas exploration and production company. It is engaged in acquiring, exploring and developing conventional and shale oil and gas assets across Europe and North Africa. The company holds interests in Durresi Block located in offshore Albania and inc …
  • The Cheesecake Factory Incorporated:企業の戦略・SWOT・財務分析
    The Cheesecake Factory Incorporated - Strategy, SWOT and Corporate Finance Report Summary The Cheesecake Factory Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • EyeGate Pharmaceuticals Inc (EYEG)-製薬・医療分野:企業M&A・提携分析
    Summary EyeGate Pharmaceuticals Inc (EyeGate) is a clinical-stage specialty pharmaceutical company that offers eye care medicines. The company offers macular edema and non-infectious anterior uveitis. It offers technologies for most prevalent issues in ophthalmic care; the existing lack of patient a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆